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Introduction . Prevalence of estrogen (ER), progesterone (PgR) and human epidermal growth factor receptors (HER2) 
vary by age among women with breast cancer (BC). Such variation has a large significance for the prognosis and treat-
ment process. This study characterizes the prevalence of breast cancer subtypes by age in a hospital sample in Poland. 
Material and methods . The study population included 735 women with BC aged 27–91 years old (ICD-10: C50) and 
treated in the years 2009–2011 in the Military Institute of Medicine in Warsaw. Subjects were divided into 2 age ca-
tegories — 27–44 and 45+ — which included 66 (9%) and 669 (91%) women respectively. In each group prevalence 
of PgR, ER and HER2+ receptors was investigated.
Results . In both age groups the most frequent BC subtype was luminal A (hormone dependent BC — with PgR and ER 
receptor expression) — 27–44 years old — 44% and 45+ years old — 56%. The lowest number of cases in the age group 
27–44 was luminal B (triple positive breast cancer) — about 15% of cases and for 45+ age group — HER2+ BC — about 11%. 
Discussion . Performed research shows relationship between growing age of diagnosis and presence of more desirable 
features of BC among women aged 55 and more, such as expression of steroid receptors or lack of expression of HER2 
receptors, which is a good prognostic indicator for treatment outcomes. In the same time, many studies suggest that 
more aggressive types of breast cancer (basal-like — triple negative) are more characteristic for younger age groups 
(under 45 years old and younger women in perimenopausal age). Same results have been obtained in own study. 
Conclusions . A high incidence of BC in older age groups (45+) and more frequent occurrence of aggressive types 
of BC among younger women (27–44 years old) indicate the need to educate women from both age groups about 
risk factors and early symptoms of the disease. As we still have not recognized all BC risk factors, education about 
well-known agents, such as alcohol intake, overweight and obesity, play significant role in decrease of BC incidence 
and mortality. 
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Introduction
Mammary gland cancer, commonly called breast cancer 
(BC) is the most frequent malignant cancer among women 
in developed and developing countries [1]. In Poland BC in-
cidence has doubled during last three decades. According 
to the latest Polish National Cancer Registry data in Poland in 
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2015, there were 18 106 cases of BC (age standardized rate/100 
000 — 90.9) and 6319 deaths caused by BC (age standardized 
rate/100 000 — 31.79). BC is the most common malignant can-
cer among women in Poland and is the second cause of cancer 
mortality (after lung cancer, which is the leading cause) [2].
The clinical characteristics of BC have significant im-
portance for the treatment process and also for further 
prognosis [3–5]. There are four main subtypes of BC, which 
were featured in view of expression or lack of expression of 
specific receptors in BC cells:
 — Luminal A with expression of steroid receptors — estro-
genic — ER and progesteronic – PgR and lack of expres-
sion of HER2 receptor (human epidermal growth factor), 
 — Luminal B with simultaneously expression of steroid re-
ceptors and HER2 receptor (triple positive breast cancer),
 — HER2+ with HER2 receptor expression (with simultane-
ously lack of steroid receptors expression),
 — Basal-like with lack of expression of steroid receptors 
and HER2 receptor (triple negative breast cancer) [6, 7].
Expression of steroid receptors ER, PgR and receptor HER2 
is a relevant predictive and prognostic factor in BC. In case 
of disease with expression of ER and PgR receptors, patients 
have better prognosis because of more effective response to 
treatment. Increased expression of these receptors is favor-
able — it gives better response to hormonal therapy. Lack 
of ER and PgR receptors leads to increased risk of metastasis. 
The activity of HER2 receptor contributes to intensified BC 
development. HER2 receptor is responsible, among others, 
for multiplication of cells, restriction of apoptosis and causes 
intensified angiogenesis. Patients with HER2 receptor ex-
pression have worse prognosis of the course of the disease 
— there is a higher risk of metastasis occurrence, higher 
malignancy and relapse of the disease. This is also a prem-
ise for using monoclonal antibodies treatment [8, 9]. BC in 
which presence of steroid and HER2 receptors is not stated 
is characterized by the worst prognosis and severe course 
with frequent relapses. For this group of women targeted 
treatment is not available [10]. Among BC patients prevalence 
of PgR, ER and HER2 receptors is diverse (this also applies to 
their absence). The table below (Tab. I) shows the prevalence. 
Material and methods
The material for the study was clinical data on prevalen-
ce of steroid and HER2 receptors among women with BC 
(ICD-10: C50) in the age groups 27–44 and 45+ years old. 
Tissue sections were taken from women with BC, treated 
in the years 2009–2011 in the Military Institute of Medicine 
in Warsaw, Poland. Obtained biological material has been 
stained using immunohistochemistry methods and all per-
sonal data of the patients has been anonymized. Primary 
research group consisted of 1116 patients in the age of 
27–91 years old. However, because of the fact that in the 
diagnostic process in some cases there were doubts about 
the expression of specific receptors, these cases have not 
been included in the final research group that consisted 
of 735 patients. The group has been divided into 2 age 
categories: 27–44 and 45+ years old which consisting of 
66 (9%) and 669 (91%) women respectively. The criterion 
for group division was perimenopausal age — 45 years old. 
Additionaly data have been divided into 4 following groups 
by hormone profile: 
 — presence of progesterone and estrogen receptors with 
lack of HER2 receptor (luminal A),
 — presence of progesterone, estrogen and HER2 receptors 
(luminal B),
 — lack of progesterone and estrogen receptors with pre-
sence of HER2 receptor (HER2+),
 — lack of progesterone, estrogen and HER2 receptors (ba-
sal-like).
Data were also grouped by age into 14 five-years age 
ranges: 20–24, 25–29, …, 80–84, 85 years and more. Data 
were analyzed with the use of Microsoft Excel Software 
ver. 15.22 (160506) and Jointpoint Trend Anylysis Software 
ver. 4.5.0.1. Level of statistical significance was set to alpha 
= 0.05.
Limitations of the study
As the study is based on preliminary data only, some 
limitations have occurred. We did not analyse all of the 
biological aspects of BC, such as HER2 amplification or Ki67 
expression and others, but only the chosen ones. Moreover, 
we decided to limit the size of the sample and include only 
fully confirmed cases.
Results
In the age group 27–44 years old, 15.2% of women had 
BC with expression of ER, PgR and HER2 receptors (luminal 
B) which constituted the lowest percent of all BC types in 
analysed age group. 16.7% patients had breast cancer with 
HER2 receptor expression (HER2+ without steroid receptors 
expression). Further, 24.2% of women had basal-like BC 
without ER, PgR and HER2 receptors expression. The big-
gest group constituted women with BC with expression of 
ER and PgR receptors, without HER2 receptor expression 
(luminal A) — 43.9%. 
In the age group 45 years old and older, the lowest 
percent was breast cancer with HER2 receptor expression — 
Table I . Prevalence of PgR, ER and HER2+ receptors in breast cancer 
[2], [10], [11]
Receptor Estimated prevalence in BC
ER 80%
PgR 40–70%
HER2 20–30%
– (basal-like breast cancer) 15–20%
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11,1% of women. Triple negative breast cancer constituted 
15,1% of all cases in this age group, triple positive — 18%. 
The most frequent was breast cancer with steroid receptors 
expression (PgR, ER) — 55,8% (Fig. 1). 
In the analyzed two age groups there is an analogy con-
cerning the most frequent type of breast cancer. Luminal A 
BC (with ER and PgR expression) was identified among the 
highest percent of women in the age group 27–44 years old 
— 43.9% and in the age group 45+ — almost 56%. Luminal 
B BC occurred among the lowest percent of women in the 
age group 27–44 years old — 15.2%, meanwhile in the age 
group 45+ the lowest number was BC with HER2 receptor 
expression (without steroid receptors expression) — 11.1%. 
Considering all BC types in all investigated age groups, 
BC occurs most often among women between 45 and 60 
years old. The biggest difference in the number of cases was 
observed between luminal A and other types of this disease. 
In case of other three types of BC (basal-like, luminal B and 
HER2+) in the age group 27–91 years old, the difference in 
the number of cases between these groups was not signi-
ficant (Fig. 2.).
Prevalence of basal-like BC increases with women’s age 
up to the age of 55. Average percentage change in subse-
quent 5-years age groups was 7.3% [95% CI = (1.9; 13.1)]. 
After the age of 55 prevalence of this type of BC decrease. 
Average percentage change (APC) in the 5-years age groups 
was 4.9% [95% CI = (–8.9; –0.7)].
Luminal B BC prevalence increases with age up to 
the age of 50. Average percentage change in subsequent 
5-years age groups was 12.1% [95% CI = (4.3; 20.4)]. After the 
age of 50 prevalence of this type of BC did not change at the 
assumed significance level: APC = 3% [95% CI = (–6.1; 0.2)]. 
Prevalence of luminal A BC increases with women’s age 
up to the age of 45. APC in 5-years groups was 19.6% [95% CI 
= (5.9; 35.1)]. Prevalence of this type of BC stabilizes among 
women in the age group 45–60 years old with APC = 6.5% 
[95% CI = (–9.8; 3.1)] in subsequent 5-years age groups.
In the investigated group, prevalence of BC with HER2 
expression receptor increases with age up to the age of 
60. APC in subsequent 5-years age group was 5.7% [95% 
CI = (1.2; 10.3)]. After this age (60 years old) prevalence of 
HER2+ BC decreases. APC in 5-years age groups was 7.7% 
[95% CI = (–14.8; –0.1)].
Discussion 
In our study the most frequent type of BC regardless of 
age was luminal A BC (hormone-dependent breast cancer 
with expression of ER and PgR receptors (and without 
HER2 expression). The results indicate that this type of 
BC is more common among women aged 45 and older 
(in perimenopausal and postmenopausal age), affecting 
almost 60% of women with BC, while in the age group 
27–45 it was about 44% of women. Dębska and Potemski 
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Table II . Breast cancer by age group and hormone profile
Age group Number of cases 
(n)
Luminal B HER2+ Basal-like Luminal A
20–44 66 10 11 16 29
45+ 669 121 74 101 373
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Figure 1 . Breast cancer prevalence by hormone profiles in the age 
groups 27–44 and 45+ years old
Figure 2 . Hormone profile of women with breast cancer in the age of 
27 years old and older
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reported similar conclusions, finding that 75% of women 
with diagnosed BC have steroid receptors expression. Ad-
ditionally, this regularity is more characteristic for women 
in postmenopausal age [12]. De Kruijf et al. also show a 
relationship (p < 0.02) between ER, PgR receptors expres-
sion and age (research group — 822 women with BC) 
[13]. Some research indicates a relationship between a 
woman’s age at BC diagnosis time and their prognosis for 
recovery. Diab et al. show in their study performed on two 
cohorts of women with BC (50 828 and 256 287 patients) a 
relationship between increasing age of diagnosis and the 
presence of more desirable features of BC among women 
aged 55 and older, such as expression of steroid receptors 
or lack of expression of HER2 receptors, which is a good 
prognostic indicator for treatment outcomes [14]. 
According to Kolečkova’s et al. study, which investigated 
BC tissue from 632 women in terms of presence of steroid 
receptors, HER2 receptor expression and corelation with 
age, the most agressive BC types (basal-like and HER2+ BC) 
are more prevalent in younger age groups — 20–39 years 
old women. This study also shows a correlation between 
occurance of estrogene receptors — ER and age of women 
with BC (p < 0.0001) [15]. De Kruijf et al. also indicate a re-
lationship (p < 0.02) between younger age of women and 
more frequent basal-like BC occurence [13]. 
Our analysis leads to similar conclusions — basal-like 
BC and HER2+ BC occurred in 24.2% and 16.7% of cases 
respectively in the younger age group, while among women 
in the age of 45 and older it was 15.1% and 11.1% of cases 
respecitvely. Less aggressive types of breast cancer with 
presence of ER and PgR receptors were more characteristic 
for women in older age groups both in Kolečkova’s et al. 
and in our study.
Anders et al. shows less frequent occurrence of steroid 
receptors with simultaneous presence of more frequent HER2 
receptor expression among younger women. Analysis carried 
out on the group of women counted 784 patients with early 
BC proves that BC among young women is a specific type of 
this disease and it is kind of  “unique biological unit” [16]. Mo-
reover, Anders et al. in other study underline that prognosis 
of survival for women with diagnosed BC under of the age 
of 40 years is much worse in comparison to older patients. 
Younger age in BC is an independent factor contributing to 
worse prognosis for the course of treatment [17]. 
A study carried out by Jenkins et al. among 3947 women 
with BC also shows that with increasing age of women, the 
number of cases of luminal A BC grows with simultaneously 
decrease of basal-like BC cases. However, authors of the 
study claim that taking into the consideration each type 
of BC, the age of diagnosis is not independent prognostic 
factors for treatment effects [18]. 
From studies cited by Ribnikar et al. performed in two re-
search groups counted respectively 1427 and 9885 women 
with BC it follows that in perimenopausal age (women in 
the age about 50 years old) lack of ER and/or PgR receptors 
and expression of HER2 receptor were observed, especially 
among younger women. Similar conclusions have been 
developed in own studies [19]. 
Conclusions
Conducted study confirms that prevalence of specific 
receptor profiles in BC patients varies by age of the women. 
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Figure 3 . Hormone profile of women with breast cancer in the age 
group 20–44 years old
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Figure 4 . Hormone profile of women with breast cancer in the age 
group 45 years old and older
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BC with HER2 receptor expression and basal-like BC are 
more characteristic for younger age group — 27–44 years 
old. Luminal A and luminal B BC are more frequent among 
patients aged 45 and older. 
The border point for significant increase of number of 
BC cases was perimenopausal age (about 45 years old), 
which may suggest that the change of women’s hormonal 
status plays a key role for BC development, regardless its 
receptor profile. 
High incidence of BC in older age group (45+) and more 
frequent occurrence of aggressive types of BC among youn-
ger women (27–44 years old) indicate a need of education 
of women from both age groups about risk factors and early 
symptoms of the disease. However, taking into considera-
tion the increasing incidence of BC among younger women, 
this group should be a subject of particular interest.
As we still do not know enough about BC origin and 
treatment options for some women with BC are limited 
(basal-like BC), primary prevention and mammography re-
main efficient tools in BC incidence and mortality reduction.
Primary prevention of well-known factors contributing 
to BC (for example obesity and overweight, alcohol con-
sumption, diet rich in saturated fats) is even more important 
when we consider features of BC in the research group and 
general population. Receptor profile of BC has significant 
meaning for treatment process. In the investigated group 
the most frequent was luminal A BC with best prognosis. 
Early detection of this type of BC may contribute to more 
effective treatment, shortening the treatment time and in 
the long term may lead to mortality reduction and savings 
for health care systems. Similarly, in case of more aggressive 
BC types (basal-like and HER2+ BC) effective actions for early 
detection may contribute to mortality reduction, also in the 
younger age group. 
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